Vesalion technology reduces infarct size in large STEMI clots

Vesalion's enVast-assisted mechanical thrombectomy technology has demonstrated its ability to reduce infarct size in patients experiencing STEMI (ST-elevation myocardial infarction) with a large thrombus burden. The results, presented at ESC Congress 2026, showed a significant reduction compared to conventional percutaneous coronary intervention (PCI).

This outcome is significant for cardiovascular care, as large clots can pose considerable challenges for intervention and impact treatment efficacy. The primary endpoint of the NATURE randomized controlled trial was met, underscoring the technology's potential to improve patient prognosis.

The study's presentation in the Late-Breaking Science session at the European Society of Cardiology congress highlights its clinical relevance. Vesalion's technology aims to provide a more effective and potentially safer method for managing previously difficult-to-treat coronary blockages.

The company announced the findings in Dallas, Texas, on August 29, 2026. The results support the use of the enVast system in treating heart attacks, potentially offering a new standard of care for patients with significant clot burden.